Sandip Panicker, Ph.D.
Affiliations: | University of California, San Diego, La Jolla, CA |
Area:
GIRK channels, addiction, plasticity, G proteinsGoogle:
"Sandip Panicker"Mean distance: 15.26 (cluster 6) | S | N | B | C | P |
Parents
Sign in to add mentor| Paul A. Slesinger | grad student | 2004 | UCSD | |
| (Structural rearrangement in the pore of a ligand gated ion channel during gating.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Simmons KT, Chan J, Hussain S, et al. (2023) Anti-C1s humanized monoclonal antibody SAR445088: A classical pathway complement inhibitor specific for the active form of C1s. Clinical Immunology (Orlando, Fla.). 251: 109629 |
| Freire PC, Muñoz CH, Derhaschnig U, et al. (2019) Specific inhibition of the classical complement pathway prevents C3 deposition along the dermal-epidermal junction in bullous pemphigoid. The Journal of Investigative Dermatology |
| Nikitin PA, Rose EL, Byun TS, et al. (2019) C1s Inhibition by BIVV009 (Sutimlimab) Prevents Complement-Enhanced Activation of Autoimmune Human B Cells In Vitro. Journal of Immunology (Baltimore, Md. : 1950) |
| Jäger U, D'Sa S, Schörgenhofer C, et al. (2018) Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial. Blood |
| Bartko J, Schoergenhofer C, Schwameis M, et al. (2018) A randomized, first-in-human, healthy volunteer trial of BIVV009, a humanized antibody for the specific inhibition of the classical complement pathway. Clinical Pharmacology and Therapeutics |
| Nikitin PA, Rose EL, Byun TS, et al. (2018) C1s inhibition by BIVV009 prevents complement-enhanced activation of autoimmune human B cells in vitro Molecular Immunology. 102: 193 |
| Byun T, Singh A, Parry G, et al. (2018) Antibody-mediated complement activation is strictly classical pathway driven in human serum but classical and lectin in rat serum Molecular Immunology. 102: 137 |
| Eskandary F, Jilma B, Mühlbacher J, et al. (2017) Anti-C1s Monoclonal Antibody BIVV009 in Late Antibody-Mediated Kidney Allograft Rejection - Results from a First-in-Patient Phase 1 Trial. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons |
| Mühlbacher J, Jilma B, Wahrmann M, et al. (2017) Blockade of HLA Antibody-Triggered Classical Complement Activation in Sera From Subjects Dosed With the Anti-C1s Monoclonal Antibody TNT009-Results from a Randomized First-in-Human Phase 1 Trial. Transplantation. 101: 2410-2418 |
| Kasprick A, Holtsche MM, Rose EL, et al. (2017) The anti-C1s antibody TNT003 prevents complement activation in the skin induced by bullous pemphigoid autoantibodies. The Journal of Investigative Dermatology |